Literature DB >> 7507892

Local immune response and protection in the guinea pig keratoconjunctivitis model following immunization with Shigella vaccines.

A B Hartman1, L L Van de Verg, H H Collins, D B Tang, N O Bendiuk, D N Taylor, C J Powell.   

Abstract

This study used the guinea pig keratoconjunctivitis model to examine the importance of route of administration (mucosal versus parenteral), frequency and timing of immunization (primary versus boosting immunization), and form of antigen given (live attenuated vaccine strain versus O-antigen-protein conjugate) on the production of protective immunity against Shigella infection. Since local immune response to the lipopolysaccharide (LPS) O-antigen of Shigella spp. is thought to be important for protection against disease, O-antigen-specific antibody-secreting cells (ASC) in the spleen and regional lymph nodes of immunized animals were measured by using an ELISPOT assay. Results indicated that protective efficacy was associated with a strong O-antigen-specific ASC response, particularly in the superficial ventral cervical lymph nodes draining the conjunctivae. In naive animals, a strong ASC response in the cervical lymph nodes and protection against challenge were detected only in animals that received a mucosal immunization. Protection in these animals was increased by a boosting mucosal immunization. While parenteral immunization alone with an O-antigen-protein conjugate vaccine did not protect naive animals against challenge, a combined parenteral-mucosal regimen elicited enhanced protection without the addition of a boosting immunization. Although O-antigen-specific serum immunoglobulin A titers were significantly higher in animals receiving a mucosal immunization, there was no apparent correlation between levels of serum antibody and protection against disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7507892      PMCID: PMC186123          DOI: 10.1128/iai.62.2.412-420.1994

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  33 in total

1.  Studies in shigellosis. III. A controlled evaluation of a monovalent Shigella vaccine in a highly endemic environment.

Authors:  A R HIGGINS; T M FLOYD; M A KADER
Journal:  Am J Trop Med Hyg       Date:  1955-03       Impact factor: 2.345

2.  Natural immunity to shigellosis in two groups with different previous risks of exposure to Shigella is only partly expressed by serum antibodies to lipopolysaccharide.

Authors:  D Cohen; M S Green; C Block; R Slepon; Y Lerman
Journal:  J Infect Dis       Date:  1992-04       Impact factor: 5.226

3.  Oral administration of a streptococcal antigen coupled to cholera toxin B subunit evokes strong antibody responses in salivary glands and extramucosal tissues.

Authors:  C Czerkinsky; M W Russell; N Lycke; M Lindblad; J Holmgren
Journal:  Infect Immun       Date:  1989-04       Impact factor: 3.441

4.  Serum antibodies to lipopolysaccharide and natural immunity to shigellosis in an Israeli military population.

Authors:  D Cohen; M S Green; C Block; T Rouach; I Ofek
Journal:  J Infect Dis       Date:  1988-05       Impact factor: 5.226

5.  Priming and suppression of the intestinal immune response to cholera toxoid/toxin by parenteral toxoid in rats.

Authors:  N F Pierce; F T Koster
Journal:  J Immunol       Date:  1980-01       Impact factor: 5.422

6.  Small-animal model to measure efficacy and immunogenicity of Shigella vaccine strains.

Authors:  A B Hartman; C J Powell; C L Schultz; E V Oaks; K H Eckels
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441

7.  Effect of parenteral immunization on the intestinal immune response to Salmonella typhi Ty21a.

Authors:  B D Forrest; J T LaBrooy; C E Dearlove; D J Shearman
Journal:  Infect Immun       Date:  1992-02       Impact factor: 3.441

8.  Boosting of secretory IgA antibody responses in man by parenteral cholera vaccination.

Authors:  A M Svennerholm; J Holmgren; L A Hanson; B S Lindblad; F Quereshi; R J Rahimtoola
Journal:  Scand J Immunol       Date:  1977       Impact factor: 3.487

9.  Induction of a mucosal antitoxin response and its role in immunity to experimental canine cholera.

Authors:  N F Pierce; W C Cray; B K Sircar
Journal:  Infect Immun       Date:  1978-07       Impact factor: 3.441

10.  Genotypic and phenotypic characterization of an aroD deletion-attenuated Escherichia coli K12-Shigella flexneri hybrid vaccine expressing S. flexneri 2a somatic antigen.

Authors:  J W Newland; T L Hale; S B Formal
Journal:  Vaccine       Date:  1992       Impact factor: 3.641

View more
  13 in total

1.  Construction and characterization of a live attenuated vaccine candidate against Shigella dysenteriae type 1.

Authors:  S R Klee; B D Tzschaschel; I Fält; A Kärnell; A A Lindberg; K N Timmis; C A Guzmán
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

2.  Specificity of monoclonal antibodies elicited by mucosal infection of BALB/c mice with virulent Shigella flexneri 2a.

Authors:  A B Hartman; L L Van de Verg; C R Mainhart; B D Tall; S J Smith-Gill
Journal:  Clin Diagn Lab Immunol       Date:  1996-09

3.  Parameters underlying successful protection with live attenuated mutants in experimental shigellosis.

Authors:  M L Bernardini; J Arondel; I Martini; A Aidara; P J Sansonetti
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

4.  Outer membrane protein of Neisseria meningitidis as a mucosal adjuvant for lipopolysaccharide of Brucella melitensis in mouse and guinea pig intranasal immunization models.

Authors:  L L Van De Verg; A B Hartman; A K Bhattacharjee; B D Tall; L Yuan; K Sasala; T L Hadfield; W D Zollinger; D L Hoover; R L Warren
Journal:  Infect Immun       Date:  1996-12       Impact factor: 3.441

5.  Construction of a stable attenuated Shigella sonnei DeltavirG vaccine strain, WRSS1, and protective efficacy and immunogenicity in the guinea pig keratoconjunctivitis model.

Authors:  A B Hartman; M M Venkatesan
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

6.  Antibody and cytokine responses in a mouse pulmonary model of Shigella flexneri serotype 2a infection.

Authors:  L L van de Verg; C P Mallett; H H Collins; T Larsen; C Hammack; T L Hale
Journal:  Infect Immun       Date:  1995-05       Impact factor: 3.441

7.  Construction and characterization of bivalent Shigella flexneri 2a vaccine strains SC608(pCFAI) and SC608(pCFAI/LTB) that express antigens from enterotoxigenic Escherichia coli.

Authors:  Ryan T Ranallo; C Piyumi Fonseka; Fred Cassels; Jay Srinivasan; Malabi M Venkatesan
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

8.  Native and mutant forms of cholera toxin and heat-labile enterotoxin effectively enhance protective efficacy of live attenuated and heat-killed Shigella vaccines.

Authors:  A B Hartman; L L Van De Verg; M M Venkatesan
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

9.  The Galleria mellonella larvae as an in vivo model for evaluation of Shigella virulence.

Authors:  Shoshana Barnoy; Hanan Gancz; Yuewei Zhu; Cary L Honnold; Daniel V Zurawski; Malabi M Venkatesan
Journal:  Gut Microbes       Date:  2017-02-13

10.  Transcutaneous immunization using colonization factor and heat-labile enterotoxin induces correlates of protective immunity for enterotoxigenic Escherichia coli.

Authors:  Jianmei Yu; Frederick Cassels; Tanya Scharton-Kersten; Scott A Hammond; Antoinette Hartman; Evelina Angov; Blaise Corthésy; Carl Alving; Gregory Glenn
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.